Form 4: Enliven Therapeutics Executive Joseph P. Lyssikatos Exercises Options and Sells Shares
SEC Form 4 Filing
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares on May 29, 2024, according to a Form 4 filing with the SEC.
Summary
- On May 29, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, exercised options to acquire 12,000 shares of common stock at a price of $1.12 per share.
- Simultaneously, Lyssikatos sold 9,877 shares at a weighted average price of $21.564 and 2,123 shares at a weighted average price of $22.5212.
- Following these transactions, Lyssikatos directly owns no shares of common stock and indirectly owns 1,117,035 shares through The Lyssikatos Revocable Trust 12/15/2011.
- He also holds options for 206,550 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions related to executive compensation and pre-planned stock sales. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Insider transactions are routinely monitored by investors to gauge executive sentiment and potential future performance of the company. Option exercises followed by sales are a common way for executives to realize value from their compensation packages.
Comparison to Industry Standards
- It's common for executives at publicly traded biotech companies like Enliven Therapeutics to have compensation packages that include stock options.
- The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading, similar to executives at companies like Amgen or Gilead Sciences.
- The size of the transactions is relatively small compared to the overall market capitalization of Enliven Therapeutics, which is typical for routine executive compensation realization.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares sold compared to the overall market capitalization.
- The transactions reflect part of the executive's compensation and do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/15/2011 | Date of The Lyssikatos Revocable Trust |
| 06/26/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 05/29/2024 | Date of option exercise and share sales |
| 05/31/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.